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 Nitroglycerin (NTG) is medication used to reduce chest pain (Boden et al., 2015) 
and is the suggested analgesic for angina associated with ST elevation myocardial 
infarction (STEMI) (de Alencar Neto, 2018). Due to the potential for right ventricular 
(RV) infarct and hemodynamic collapse in inferior STEMI patients (Nagam, Vinson, & 
Levis, 2017), the American Heart Association (AHA) recommends avoidance of NTG in 
patients with suspected RV infarct (Antman et al., 2004). The purpose of this DNP 
project was to explore the safety of NTG use in the treatment of patients diagnosed with 
STEMI by evaluating the effects of NTG on hemodynamic measures and angina. Data 
were collected via a retrospective chart review at a rural Midwestern hospital and 
analyzed via Fisher’s Exact and multiple linear regression analyses. There were no 
significant differences between STEMI groups for occurrence of hypotension (p=0.521), 
bradycardia (p=0.064), medical need for hemodynamic support (p=0.530), or cardiac 
arrhythmia (p=0.465). For this sample of patients, the results show no difference in 
adverse occurrences between patients who received NTG with a diagnoses of inferior 
STEMI versus patients who received NTG with a diagnoses of non-inferior STEMI. A 
recommendation is that patients with identified inferior STEMI receive a right-sided 





patient care including the use of NTG, which was shown to significantly reduce chest 
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Nitroglycerin (NTG) is the most commonly prescribed short-acting nitrate to 
reduce the intensity of chest pain in those experiencing angina (Boden, Padala, Cabral, 
Buschmann, & Sidhu, 2015). NTG is a front-line medication used to relieve chest pain in 
individuals experiencing acute coronary syndrome (ACS) (Boden et al., 2015) and is also 
the most frequently delivered treatment to individuals having a myocardial infarction 
(MI) (Ferreira & Mochly-Rosen, 2012). Although there is no study identifying reduction 
of mortality, NTG remains a suggested analgesic medication for angina associated with 
ST elevation myocardial infarction (STEMI) as well as for the treatment of hypertension 
(de Alencar Neto, 2018).  
ACS represents the signs and symptoms a person experiences relating to 
myocardial ischemia or infarction, with or without electrocardiogram (ECG) ST segment 
changes (Camm & Camm, 2016) and includes unstable angina, non-ST elevation 
myocardial infarction (NSTEMI) and STEMI. The most damaging and life-threating 
diagnosis associated with ACS is STEMI. The diagnosis of STEMI occurs when there is 
complete occlusion of a coronary artery causing cardiac tissue death, which is the cause 
of angina, and is identified by ST segment elevation on an ECG (Camm & Camm, 2016). 
The purpose of this DNP project was to explore the safety of NTG use in the treatment of 
patients diagnosed with STEMI by evaluating the effects of NTG on hemodynamic 







Significance and Background 
The American Heart Association (AHA) continues to designate cardiovascular 
disease as the leading cause of mortality for both men and women in the United States 
(Benjamin et al., 2018). Between the years 2011 and 2014, there were 8.7 million 
individuals diagnosed with angina, and in 2014 alone, there were 957,000 individuals 
diagnosed with MIs (Benjamin et al., 2018). The total number of individuals with angina 
and MIs suggests a significant number of individuals who may have received NTG or 
been provided with a NTG prescription. The rapid onset of NTG effects results in venous 
and arterial dilation, ultimately increasing blood flow to the heart and reducing 
myocardial stress, which are desired during a STEMI (Ferreira & Mochly-Rosen, 2012). 
Currently, the AHA advises extreme caution with the use of NTG, or against the 
use of NTG entirely, with inferior STEMIs with potential right ventricular (RV) 
infarction and failure (Antman et al., 2004, O’Connor et al., 2010). RV infarction most 
commonly occurs with the occlusion of the marginal branch of the right coronary artery 
(RCA), resulting in dyskinetic RV wall motion, decreased compliance of the ventricle, 
and subsequent reduced stroke volume (Namana et al., 2018). Clinical indications that are 
more specific to RV infarction and pending RV failure include elevated jugular 
distention, clear lung sounds with auscultation, hypotension, pulsus parodoxus, and a 
tricuspid murmur (Namana et al., 2018).  
The reasoning behind avoiding NTG use in patients with potential RV 
involvement is that the medication could potentiate hypotension and cardiac arrhythmias 
(Antman et al., 2004, O’Connor et al., 2010). An inferior STEMI, which is identified on a 





2014), often indicates occlusion of the RCA (Namana et al., 2018). Because occlusion of 
this coronary artery is also is the most common to cause RV infarct, concern for RV 
involvement may influence clinical interventions. 
Inferior wall MIs represent 40% to 55% of all MIs (Jaton, 2017; Warner & 
Tivakaran, 2020), while the occurrence of right ventricle (RV) infarct has been reported 
to occur in approximately 20% to 50% of inferior STEMIs (Bischof, Worrall, & Smith, 
2018; Nagam, Vinson, & Levis, 2017). A standard 12-lead ECG provides limited data on 
RV infarct (Nagam et al., 2017), and therefore, it is recommended that a right-sided ECG 
be obtained when there is inferior STEMI identification on a standard 12-lead ECG 
(Antman et al., 2004).  
Nagam et al. (2017) discuss how a conventional 12-lead ECG largely shows 
involvement of the left ventricle, while minimally showing RV wall involvement. A 
right-sided ECG analyzes leads V1R-V6R, allowing for improved evaluation of the RV 
(Somers, Brady, Bateman, Mattu, & Perron, 2003). With the right-sided ECG, precordial 
leads mirror the locations of the standard 12-lead but on the right side of the patient’s 
chest (Somers et al., 2003). Because lead V4R has high sensitivity and specificity for 
identifying RV involvement, when obtained via a right-sided ECG, this lead may provide 
pertinent information on the status of the RV and help guide treatment of patients 
diagnosed with inferior STEMI (Nagam et al., 2017; Somers et al., 2003). 
 NTG has systemic venous dilating properties, which reduces cardiac preload 
(Ferreira & Mochly-Rosen, 2012) and may contribute to hypotension and decreased 
cardiac output, especially in those with RV infarct (Antman et al., 2004). The effects of 





resulting in temporary coronary artery dilation. Higher doses of intravenous infusions 
between 160 and 600 micrograms per minute result in sustained systemic arterial and 
venous dilation (Jaton, 2017). The effects of NTG are transient and the benefits of NTG 
for angina reduction in patients with inferior STEMIs requires evaluation on a patient-
specific basis. 
The use of opioid medications, such as morphine (de Alencar Neto, 2018), as an 
analgesic for angina should be avoided unless angina is unresponsive to NTG (Frampton, 
Devries, Welch, & Gersh, 2020). Evaluation of morphine, which was traditionally used to 
reduce angina during ACS and STEMIs, has been shown to reduce the therapeutic effects 
of commonly used medications, such as ticagrelor, prasugrel, and clopidogrel, all of 
which are used for platelet inhibition before and after percutaneous coronary intervention 
(PCI) (Frampton et al., 2020; Ibanez et al., 2018). Although morphine is still listed as a 
potential analgesic for angina resulting from STEMI (Antman et al., 2008), it should be 
noted that newer research implies the risks of reducing therapeutic effects of antiplatelet 
medications outweigh the benefits of morphine and potentially other opioids for analgesia 
(Duarte et al., 2019; Frampton et al., 2020; Koh, Fernando, Peter, & Stub, 2019). 
Treating angina associated with STEMI becomes challenging when risks could impact 
patient morbidity and mortality. An individualized approach to patient care requires 
ongoing analysis of the safety and efficacy of medications currently used in the treatment 
of STEMI. 
Purpose of DNP Project 
 The purpose of this DNP project was to explore the safety of NTG use in the 





hemodynamic measures and angina. Comparisons occurred between patients who 
received NTG with the diagnosis of inferior STEMI to those diagnosed with non-inferior 
STEMI, all of whom presented to a rural Midwestern hospital for treatment. The hospital 
used in this project serves as the only PCI center in a large geographical region spanning 
approximately 16,000 square miles, providing services to individuals that reside in the 
town in which the hospital is located, as well as to individuals in the many surrounding 
rural communities. NTG administration was tracked retrospectively via healthcare 
professionals’ documentation, in order to assess the safety implications of using NTG for 
angina reduction in this rural area. As the development of hemodynamic instability is a 
major concern resulting from administration of NTG to patients with inferior STEMIs 
due to RV infarct (Antman et al., 2004), the following research questions were explored: 
1) Does the administration of NTG result in hypotension more often in inferior 
STEMI patients than non-inferior STEMI patients?  
2) Do patients with inferior STEMIs require additional interventions more 
frequently to correct hypotension or bradycardia than non-inferior STEMI patients 
following NTG administration?  
3) Do inferior STEMI patients experience more bradycardia and cardiac 
arrhythmias compared to non-inferior STEMI patients?  
4) Does NTG significantly reduce chest pain levels reported by STEMI patients? 
Methods 
 A retrospective chart review examined charts of previously hospitalized patients 
who were diagnosed with inferior or non-inferior STEMI who presented to the rural 





pressure (SBP), heart rate, cardiac arrhythmias, need for hemodynamic interventions, and 
patient reported chest pain were compared between patients diagnosed with inferior 
STEMI to patients diagnosed with non-inferior STEMI. All patients in both groups also 
had received NTG, which was identified while examining each individual’s chart. 
 The sample consisted of patients who had received NTG in conjunction with the 
diagnosis of STEMI. The listed discharge diagnosis of STEMI, which was determined by 
a cardiology physician, was how the presence of STEMI was determined in this project. 
Data were grouped according to patient diagnoses of inferior versus non-inferior STEMI, 
and the outcome measurements of SBP, heart rate, and occurrence of cardiac arrhythmias 
were compared between the two groups. Reduction in reported angina experienced by 
patients following NTG administration was also examined for both groups, as well as the 
use of fluid resuscitation or vasopressors in response to hypotension or bradycardia 
following NTG administration.  
Theoretical Framework 
The theoretical framework used for this project was the Johns Hopkins Nursing 
Evidence-Based Practice (JHNEBP) model (© The Johns Hopkins Hospital/ The Johns 
Hopkins University, permissions viewable in Appendix A). The JHNEBP model is an 
evidence-based practice model that allows for nurses and other interdisciplinary team 
members to identify and make changes to practice in order to provide evidence-based 
individualized care to patients (McEwen & Wills, 2018). For the purposes of this project, 
results will be reported to the hospital STEMI coordinator in order to add to discussions 
on the care of patients presenting with ACS at this hospital. Based on the JHNEBP 





treatment based on current AHA guidelines for RV infarct (Antman et al., 2004), which 
may not account for individualized potentially beneficial interventions, especially in the 
absence of diagnostic measures to identify RV infarct. Specifically, this project seeks to 
add to the evidence regarding the impact of NTG on the hemodynamic outcome variables 
of SBP, heart rate, cardiac arrhythmias and chest pain experienced by patients diagnosed 
with STEMI. Ultimately, the goal of this project is to contribute data to the conversation 










RV infarct has been reported to occur in as low as 20% of patients (Bischof et al., 
2018) and as high as 50% of patients (Nagam, Vinson, & Levis, 2017) with inferior 
STEMI identification on ECG. The most common culprit lesion causing RV infarct is the 
acute marginal branch of the RCA with ST elevation on ECG in lead V1, II, III, and aVF 
(Namana et al., 2018). Although RV infarct may occur with other culprit lesions, such as 
the left circumflex artery (Namana et al., 2018), the RCA is often suspected in 
individuals with inferior STEMI identification on ECG.  
As inferior STEMIs represent approximately 40% to 55% of all STEMI cases 
(Jaton, 2017; Warner & Tivakaran, 2020), and with current recommendations to withhold 
NTG from patients with RV infarct (Antman et al., 2004), it is pertinent to include 
methods to identify RV infarct in patient care (Ibanez et al., 2018). Without proper 
identification of RV infarct in inferior STEMI patients, hesitancy in the provision of NTG 
may exist due to the associated occurrence of RCA and RV involvement observed in 
patients with inferior STEMIs (Namana et al., 2018). NTG may provide necessary 
analgesia for angina experienced by patients throughout their MI, as angina has been 
identified as a common symptom experienced by both men and women during a STEMI 
(Sederholm Lawesson et al., 2018). Recent literature has warned that angina treated with 
morphine may result in lengthened hospital admission, increased infarct size and 
subsequent higher mortality rates (McCarthy, Bhambhani, Pomerantsev, & Wasfy, 2018). 
A reason cited for these adverse effects is that morphine decreases the therapeutic action 






Nurses have an ethical standard that applies to providing evidence-supported 
analgesia to individuals experiencing pain, in addition to providing patients with 
individualized care (Stokes, 2018). With interdisciplinary involvement, healthcare 
providers should evaluate various modalities for pain reduction in patients. For acute pain 
in patients experiencing STEMI, reduction of angina needs to consider an individualized 
approach to guide the provision or withholding of medications. Re-establishment of 
blood flow to the occluded coronary artery with PCI will ultimately relive angina 
experienced by patients, however, angina should be treated to reduce myocardial stress in 
the interim (Ibanez et al., 2018). Because of the current recommendations for NTG use in 
STEMIs (Antman et al., 2004), inferior STEMI patients are potentially blanketed into a 
group that may not receive NTG with subsequent angina reduction, especially in the 
absence of interventions to specifically identify RV infarct. Although caution for adverse 
events and unwanted side effects needs to be considered in all patients with all 
medications, it is necessary to address each patient case individually and to uphold the 
ethical implications of managing pain. To provide evidence-driven and individualized 
care, it is important to evaluate the safety of NTG use between inferior STEMI and non-
inferior STEMI patients, and to question whether current practices are best for patients.  
Literature Review 
 A review of literature was conducted using Northern Michigan University’s 
online Lydia Olson Library, CINAHL, PubMed, and Google Scholar. Online searches 
focused on finding information relating to NTG, ECG, inferior STEMI, RV infarct, and 






The Use of NTG 
In a retrospective chart review of patients with suspected STEMI in a prehospital 
setting, Bosson et al. (2019) evaluated blood pressure changes, pain scores and heart rates 
after the administration of NTG. The study reviewed records from July, 2015 to 
December, 2016, from three PCI centers to which patients were transported in Los 
Angeles County, California. A 12-lead ECG was performed on patients with suspected 
cardiac-related chest pain. Suspected STEMI was determined by software analysis in 
combination with paramedic interpretation, with additional assistance provided by online 
medical control (Bosson et al., 2019). Bosson et al. (2019) describe the primary treatment 
of persistent angina was 0.4 mg sublingual NTG, which was repeated twice if pain 
persisted. Patients with initial SBP < 100 mmHg were not included in the study, as they 
were ineligible for NTG or opioid medications.  
Bosson et al. (2019) identified change in blood pressure as a key safety issue that 
was evaluated in the study in patients that received NTG compared to those who did not. 
Triage SBP < 100 mmHg, bradycardia or heart rate < 60 beats per minute, drop in 
systolic blood pressure > 30 mmHg and cardiac arrest occurring out of the hospital were 
secondary safety outcomes evaluated by the researchers. Pain was evaluated on a 0 to 10 
scale to assess for efficacy of NTG in angina reduction, which was compared to pain 
reported by individuals who did not receive NTG (Bosson et al., 2019). Subgroups, 
including individuals who received PCI to the right coronary artery (RCA), were 
evaluated for the same outcome criteria and compared to individuals who had PCI to 
other coronary arteries.  





(Bosson et al., 2019). The average chest pain score was reduced by 2.4 on a 0 to 10 point 
scale in STEMI patients treated with NTG (n=145), while all individuals who did not 
receive NTG had an average reduction in chest pain score of 1.4. Bosson et al. (2019) 
identified that a pain reduction of 1.39 was the minimum for reduction that represented 
clinical significance. When comparing chest pain reduction to the clinically significant 
value of 1.39, both groups had reduced angina, but the individuals treated with NTG had 
what was considered to be a significant reduction in angina (p <0.001), compared to those 
who did not receive NTG (p=0.5). Bosson et al. (2019) report that of the 75 patients with 
RCA occlusions, 80% received NTG. Comparable occurrence of hypotension and 
bradycardia resulted in the patients receiving PCI for non-RCA occlusions RR 0.64 (95% 
CI, 0.21, 1.95) versus those with RCA occlusion RR 1.30 (95% CI, 0.57, 2.94).  
Bosson et al. (2019) discuss the significant reduction in pain following 
administration of NTG. There also was no increased risk of hypotension or bradycardia 
with pre-hospital administration of NTG at arrival to the emergency department (ED). 
The researchers concluded that the protocols directing withholding NTG from patients 
diagnosed with inferior STEMI may need to be revisited. Limitations of the study 
included that only 193 patients of the 780 suspected actually had STEMIs, which limited 
the assessment of hemodynamics in this group. Although the number of patients with 
actual STEMI was significantly smaller than the suspected number, the researchers 
provide information on all patients as well as subgroups, which is suggested as evidence 
for the safety of NTG use in pre-hospital settings. 
In a similar study, Robichaud et al. (2016) conducted a retrospective chart review 





NTG on blood pressure in patients experiencing inferior STEMI as compared to those 
diagnosed with non-inferior STEMI. Hypotension was defined as systolic blood pressure 
(SBP) < 90 mmHg and was compared between inferior and non-inferior STEMI groups. 
Additionally, researchers evaluated any reductions in SBP > 30 mmHg between inferior 
and non-inferior patient groups. The chart review included 805 STEMI patients, all of 
whom received NTG prior to hospital arrival (Robichaud et al., 2016).  
Robichaud et al. (2016) discovered that patients with inferior STEMIs did have 
more frequent initial hypotension than non-inferior STEMI patients, with 9.9% of inferior 
STEMI patients presenting with hypotension, compared to 4.9% of patients with non-
inferior STEMIs. Patients that presented with hypotension would not meet criteria to 
receive NTG based on blood pressure regardless of infarct location, and therefore were 
not included in the study (Robichaud et al., 2016). With regard to bradycardia, 1.1% of 
inferior STEMI patients (n=5/474) experienced heart rates < 50 beats per minute, while 
no patients with non-inferior STEMIs had heart rates documented at < 50 beats per 
minute (n=0/347). 
Following statistical analyses, Robichaud et al. (2016) reported that based on 
computer-interpreted ECGs, there was no statistically significant difference in incidence 
of hypotension between inferior STEMI patients (n= 38/466, 8.2%) and non-inferior 
STEMI patients (n= 30/339, 8.9%) following NTG administration (p= 0.73). There was 
also no significant difference between the two groups for decrease in SBP > 30 mmHg, 
which occurred in 23.4% of inferior STEMI patients and in 23.9% of non-inferior STEMI 
patients (p = 0.87). Robichaud et al. (2016) described that based on the results of their 





elevation in lead II, which would suggest RV involvement, was not a good predictor for 
patients who would be at risk for developing hypotension. However, Robichaud et al. 
(2016) observed lower rates of hypotension than their expected rate of 15%, even given 
their large sample size. This was identified as a limitation to the study as, Robichaud et 
al. (2016) estimated a need to have a much larger sample size of approximately 38,000 
individuals in order to show the same occurrence of hypotension among inferior and non-
inferior STEMI groups using a power of 80%.  
Another retrospective chart review evaluating the effectiveness of sublingual 
NTG in reducing chest pain and adverse events associated with NTG administration was 
completed by Engleberg et al. (2000). The researchers reviewed all advanced life support 
(ALS) cases in the Emergency Medical Services’ (EMS) System of Suffolk County, New 
York, for which IRB approval had been granted. Patients included in this study had 
received NTG from an emergency medical technician (EMT) or paramedic prior to 
hospital arrival between January, 1993, and June, 1994. A single dose of 0.4 mg 
sublingual NTG was provided to 1,662 patients. NTG was administered to individuals 
reporting chest pain (n=901), respiratory distress likely caused from congestive heart 
failure (n=251), or a combination of both (n=510). The researchers analyzed chest pain 
rating reported by patients, hemodynamic measurements, including systolic and diastolic 
blood pressure, as well as the occurrence of adverse events.  
Of the 1,662 patients who received NTG in this study, there were a total of 779 
records with complete data on chest pain ratings. Chest pain was rated by patients using a 
verbal numeric scale ranging from 0 to 10, with 0 representing no pain and the most 





with a mean decrease in chest pain reported by patients after receiving NTG of 2.6 (95% 
CI [2.4, 2.8]). After receiving NTG, the mean SBP in all patients decreased by 11.8 
mmHg (95% CI [10.7, 13.0]), while heart rate had a mean increase by 2.7 beats per 
minute (95% CI [0.6, 4.9]). 
Engleberg et al. (2000) reported 12 adverse events within the study, which 
included patients that experienced a drop in SBP of > 100 mmHg that responded to fluid 
or elevation of the patients’ legs (n=6), hypotension following receiving NTG with a 
documented SBP of < 90 mmHg (n=4), syncope (n=1) and profound bradycardia and 
hypotension (n=1). Zero deaths were reported. Of these patients, individuals with a > 100 
mmHg decrease in SBP had initial SBP > 210 mmHg prior to receiving NTG, and no 
adverse events were associated with individuals who self-administered NTG prior to 
EMS arrival. In total, the estimated adverse events for the study were reported as 0.7% 
(95% CI [0.4, 1.3]). 
 The researchers (Engleberg et al., 2000) reported that the average reduction in 
chest pain ratings was 2.6 on the 10-point scale which equated to an approximate 40% 
reduction of pain, although pain was completely relieved in only 10% of patients. In 
discussion of limitations, Engleberg et al. (2000), point out that final diagnoses were not 
included, meaning generalizations should not be made in relation to patients experiencing 
cardiac ischemia or MI, but suggest future investigation of the effects of NTG in this 
patient population. This study documents the importance of NTG’s role in chest pain 
reduction in patients and a low occurrence of adverse events associated with 





 Bosson et al. (2019), Engleberg et al. (2000), and Robichaud et al. (2016) all cite 
a retrospective study conducted by Ferguson, Diver, Boldt, and Pasternak (1989) whom 
identified a significant occurrence of hypotension in inferior STEMI patients with 
suspected RV infarct. In discussion of their research, Ferguson et al. (1989) report 
concomitant administration of calcium channel blockers in several of the patients 
included in their study, noting that this may have potentiated the occurrence of observed 
hypotension. A prospective study to identify patients with RV infarct via multiple 
diagnostic modalities, as well as their response to NTG, was recommended by the 
researchers (Ferguson et al., 1989).  
Robichaud et al. (2016) discuss how the study conducted by Ferguson et al. 
(1989) was a singular study supporting the recommendations that currently stand about 
NTG use in inferior STEMI patients. As the occurrence of RV infarct in patients with 
inferior STEMIs is considered highly variable (Ferguson et al., 1989), the risk of using 
this medication in inferior STEMI patients with the potential of RV infarct was higher 
than the benefits. With more current retrospective reviews that refute avoidance of NTG 
in inferior STEMI patients (Bosson et al, 2019; Robichaud et al., 2016), and the apparent 
time gap in related research, it is suggested that further investigation into this topic is 
warranted.  
The Use of ECG Findings 
Another component in evaluating the safety of NTG for patients experiencing 
inferior STEMI is the use of ECG to determine RV infarct. Bischof et al. (2018) 
conducted a retrospective review of patients with inferior STEMIs to evaluate ECG 





depression or elevation in standard 12-lead ECGs. Patients included in their study were 
those that presented to Hennepin County Medical Center, Minnesota, who had ST 
elevation > 1 mm identified in inferior leads (II, III, aVF), between January, 2002 and 
March, 2008. IRB approval was granted for this project.  
Manual measurement of ST segments in leads I, II, III, aVF, aVL, V1 and V2 was 
completed by researchers (Bischof et al., 2018) and compared between patients who were 
categorized into two groups, right ventricular myocardial infarction (RVMI) and non-
RVMI. Culprit lesions were previously identified in the cardiac catheterization 
laboratory, which was the basis for categorizing patients into the respective groups. 
RVMI patients had culprit lesions identified in the RCA proximal to the RV marginal 
branch, which is the artery that supplies the RV myocardium. Non-RVMI patients had 
occlusions in the middle or distal RCA or circumflex artery. Subsequently, ST elevation 
or depression measured by researchers was compared to evaluate the sensitivity and 
specificity of ST segment changes on ECG in identifying RVMI and non-RVMI infarcts. 
 Bischof et al. (2018) reported a sample size of 43 patients in the RVMI group and 
106 patients in the non-RVMI group. In ECG analysis, there was no difference in ST 
segment depression in lead I between RVMI patients (n=37, 86%) and non-RVMI 
patients (n=85, 80%) (p=0.54), with sensitivity and specificity of lead I in determining 
RVMI reported as 86% and 20%, respectively. A lower frequency of non-RVMI patients 
had ST elevation in V1 (n=17, 16%, 95% CI [10, 24]) compared to patients with RVMI 
(n=15, 35%, 95% CI [22, 50]), which was a significant finding (p=0.015). Specificity and 
sensitivity for RVMI was thus calculated to be 84% (95%, CI [76, 90]) and 35%, 





In the absence of ST segment depression in lead V2, sensitivity for RVMI was 
found to be higher (69%, 95% CI [44, 86]) when compared to the presence of ST 
segment depression in lead V2 (15%, 95% CI [6, 32]), which was a significant finding 
(p< 0.001). In lead V1 in RVMI patients, ST segment depression was present in V2 in 
85% of patients who did not have concurrent ST segment elevation in lead V1. Bischof et 
al. (2018) thus concluded that ST segment depression in lead I was not dependable in 
differentiating patients with or without RV infarct. However, ST segment elevation in V1 
was found to be specific for RVMI, with higher sensitivity identified in the absence of ST 
segment depression in lead V2.  
Bischof et al. (2018) did identify limitations within their study, including wide 
confidence intervals and a small sample size of patients identified with RVMI. A 
prospective study was suggested, in addition to further investigation of ECG analysis in 
patients with RV dysfunction in relation to culprit lesions, which may alter sensitivity and 
specificity of leads I and V1 in identification of RV dysfunction. Due to lack of 
consistent sensitivity and specificity of leads in a standard 12-lead ECG, the researchers 
made an important recommendation, which was to obtain a right-sided ECG, specifically 
lead V4R, to accurately diagnose RV infarct (Bischof et al., 2018).  
The importance of ECG analysis for patients presenting with STEMI is magnified 
in the presence of inferior infarct identification, as treatments such as the administration 
of NTG hinge on the potential for RV infarct. The European Society of Cardiology 
(ESC), American College of Cardiology (ACC), and the AHA (Ibanez et al., 2018; 
O’Gara et al., 2013) recommend obtaining right precordial views of the heart, specifically 





STEMI identification. As completion of a right-sided ECG involves inversion of leads 
and few additional supplies, it could easily be completed in a prehospital or emergency 
room setting and provide identification of RV infarct using leads with the highest 
sensitivity for diagnosis (O’Gara et al., 2013).  
The Use of Opioid Medications 
The ESC report reduction in patients’ pain as essential during STEMI, as 
vasoconstriction occurs as a sympathetic nervous system response to pain, ultimately 
increasing the workload of the heart (Ibanez et al., 2018). The ESC states the use of 
intravenous opioids for pain should be considered but with a low level of evidence to 
support opioid use. Recommendations also warn of the effects of morphine and the 
reduction of therapeutic effects of ticagrelor, prasugrel, and clopidogrel antiplatelet 
medications (Ibanez et al., 2018) when provided to patients concomitantly. The ESC also 
recommends the administration of one of the previously mentioned antiplatelet 
medications in a prehospital setting or prior to PCI due to improved patient outcomes, 
with a high level of evidence to support the recommendation (Ibanez et al., 2018). With a 
higher level of evidence and recommendation to provide these important antiplatelet 
medications, treating pain with opioid medications, such as morphine, may be 
counterintuitive due to the reduction in antiplatelet efficacy. 
The AHA and ACC continue to list morphine as the analgesic of choice for pain 
management in patients experiencing STEMI (O’Gara et al., 2013). This is despite the 
growing research showing reduced efficacy of recommended antiplatelet medications for 
patients experiencing STEMI that receive morphine and other opioid medications 





ticagrelor, prasugrel, or clopidogrel, as soon as possible to patients prior to or at the time 
of PCI. Again, this recommendation is provided with a higher level of evidence to 
support the therapeutic effects of antiplatelet medications and improved patient outcomes 
when compared to the use of opioid medications to treat chest pain associated with 
STEMI.  
Clinical trials conducted by researchers Hobl et al. (2014) and Kubica et al. 
(2016) evaluated the effects of morphine on clopidogrel and ticagrelor, respectively. The 
results of the study conducted by Hobl et al. (2014) showed significant reduction in the 
active metabolite of clopidogrel and decreased gastric absorption of the medication in 
individuals who received morphine. Similarly, Kubica et al. (2016) reported significant 
reduced blood plasma concentrations and bioavailability of ticagrelor in individuals who 
received morphine for pain. Both clinical trials show that morphine reduces the efficacy 
of the antiplatelet medications, warranting exploration into alternative pain relief 
measures. 
The Platelet Aggregation with tiCagrelor Inhibition and FentanYl (PACIFY) trial 
was conducted by Ibrahim et al. (2018) to evaluate effects of intravenous fentanyl on 
ticagrelor. Fentanyl, which is a potent opioid medication that is frequently provided to 
patients during PCI (Ibrahim et al., 2018), was evaluated due to the previously identified 
adverse effects of morphine on antiplatelet medications. The results from this clinical 
trial showed reduction in the efficacy of ticagrelor in individuals who received fentanyl 
when compared to those who did not receive the opioid medication, indicating that 





It is suggested that opioid medications are reserved for chest pain that is 
unresponsive to NTG (Frampton et al., 2020), as commonly used opioid medications 
reduce the efficacy of important antiplatelet medications that are currently recommended 
to be provided as early as possible during a STEMI. Chest pain associated with STEMI is 
important for providers to manage (Ibanez et al., 2018; Ibrahim et al., 2018), indicating 
the need to explore medication options and their potential impact on patient outcomes. 
With the knowledge that opioid medications may reduce the efficacy of antiplatelet 
medications, the use of NTG remains a viable option in treating chest pain in patients 
experiencing STEMI.  
In summary, several studies have been conducted to evaluate the safety of NTG 
use in patients with the diagnosis of STEMI, including inferior STEMI, in relation to 
hemodynamic outcome variables, as well as to analyze NTG’s ability to reduce chest pain 
in patients (Bosson et al., 2019; Engleberg et al., 2000; Robichaud et al., 2016). Bischof 
et al. (2018) recommend other measures to identify RV infarct, due to the lack of 
sensitivity and specificity in identifying RV infarct with a standard 12-lead ECG within 
their study. Based on this literature review, further investigation into NTG use in STEMI 
patients, and specifically inferior STEMI patients, is warranted. Furthermore, patient care 
should be individualized to optimize patient outcomes, including provision of analgesic 
medication for chest pain and identification of RV infarct in patients with inferior STEMI 
identified on an ECG. The purpose of this DNP project was to explore the safety of NTG 
use in the treatment of patients diagnosed with STEMI by evaluating the effects of NTG 





to evidence for future recommendations designed to individualize care for patients, as 
well as the safe use of NTG in patients presenting with the diagnosis of STEMI.  
Theoretical Framework 
The theoretical framework that is the basis of this project is that patients should 
receive evidence-based individualized care. Nurses and interdisciplinary team members 
have the capability of identifying areas in practice that propose a certain question or 
problem, and may use the Johns Hopkins Nursing Evidence-Based Practice (JHNEBP) 
model as an evidenced-based practice model to make changes to practice (McEwen & 
Wills, 2018; Dang & Dearholt, 2018). For the purposes of this project, providing 
additional data with evidence to a hospital allows for discussions on current practice and 
contributes to debate on changes if warranted.  
The JHNEBP model consists of a question pertaining to practice, evidence 
relating to the question, and subsequent translation to practice (McEwen & Wills, 2018). 
The initial step of this theoretical model is to question certain problems or concerns that 
are identified in practice (Dang & Dearholt, 2018). For this project, it is not clear if 
inferior STEMI patients receive individualized care based on the AHA guidelines to 
withhold NTG without additional interventions, such as the recommended right-sided 
ECG.  
Following the JHNEBP model, the identification of an evidence-based practice 
(EBP) question for this project was strictly based on using a standard 12-lead ECG and 
whether exclusive standard views of the heart are enough to provide appropriate and 
patient-specific interventions to inferior STEMI patients. From this, the questions for this 





1) Does the administration of NTG result in hypotension more often in inferior 
STEMI patients than non-inferior STEMI patients?  
2) Do patients with inferior STEMIs require additional interventions more 
frequently to correct hypotension or bradycardia than non-inferior STEMI patients 
following NTG administration?  
3) Do inferior STEMI patients experience more bradycardia and cardiac 
arrhythmias compared to non-inferior STEMI patients?  
4) Does NTG significantly reduce chest pain levels reported by STEMI patients? 
As NTG is used to reduce angina, patient report of angina rating will be compared among 
inferior and non-inferior STEMI groups for analysis of therapeutic reduction in angina 
intensity. 
The initial practice question in the JHNEBP model requires recruitment of an 
interdisciplinary team. The Northern Michigan University Graduate Nursing Committee 
approval for graduate research relating to this project in conjunction with the author’s 
DNP Chair approval were the initial steps towards developing a team. Cardiologists, 
Emergency Department physicians, Emergency Medical Service (EMS) personnel, 
quality improvement and the STEMI coordinator are all key stakeholders in this project, 
as STEMI patients are cared for by several different teams prior to and at the time of PCI. 
The acronym Patient population, Intervention, Comparison, Outcome and Time table 
(PICOT) format is used in the JHNEBP model to refine the evidence-based practice 






▪ The Patient population consisted of patients with inferior and non-inferior 
STEMIs presenting to the rural Midwestern hospital for PCI intervention.  
▪ The Intervention is the administration of NTG to patients in inferior and non-
inferior STEMI groups, which was reviewed in a retrospective manner due to 
the controversy and ethics of a prospective study evaluating the same topic.  
▪ Comparison and Outcomes consisted of a comparison of data between the 
inferior and non-inferior STEMI groups in terms of hemodynamic 
measurements, additional interventions required in each group, and angina 
experienced between the two groups.  
▪ Time was defined as patients presenting to the rural Midwestern hospital 
between January 1, 2019 and December 31, 2019, with inclusion of patients 
experiencing STEMI and meeting other inclusion criteria presenting to the 
facility.  
The next section of the JHNEBP model relates to evidence. Based on the 
JHNEBP model, the problem identified is that patients are categorized into an inferior 
STEMI group and may not receive patient-specific interventions but more general 
treatment based on inferior infarct identification on a standard 12-lead ECG due to the 
potential of RV involvement. Medication, such as NTG, may be withheld based on 
guidelines for RV infarct (Antman et al., 2004), as the occurrence of RV infarct is largely 
associated with inferior STEMI. To improve quality of care and individualized care to 
patients with STEMI identification, research addressing blood pressure and patient 
hemodynamic stability between inferior and non-inferior STEMI groups should be 





the use of NTG for patients experiencing angina during a STEMI, whether an inferior or 
non-inferior infarct is identified. A review of patient charts at a rural Midwestern hospital 
was conducted to analyze the previously identified research questions. A review of 
literature with appraisal of information relating to the problem signifies the external 
search for evidence. From this, both internal and external evidence will be used to 
facilitate discussions on current policy.  
Translation of evidence to practice will depend on the fit and feasibility of 
additional interventions at the rural Midwestern hospital. Findings of internal and 
external evidence appraisal, and guidance gained from the literature on how to implement 



















 RV infarct in inferior STEMI patients has led to the recommendation by the AHA 
to use extreme caution with the use of NTG or exclude NTG entirely as a medication to 
treat chest pain in this patient population due to the possibility of hypotension and cardiac 
arrhythmias (Antman et al., 2004). Several studies (Bosson et al., 2019; Engleberg et al., 
2000; Robichaud et al., 2016) have evaluated the safety of prehospital NTG in suspected 
STEMI and actual STEMI patients, as well as the significance of NTG in chest pain 
reduction. Similar to previous studies, this DNP project explored the safety of NTG by 
evaluation of hemodynamic measures and angina in patients experiencing STEMIs in a 
rural Midwestern setting. 
Sample and Setting 
 Data collection for this DNP project was conducted at a rural Midwestern hospital 
through a retrospective chart review. The designated hospital serves as the only PCI 
center for STEMI patients in the region, providing much needed services to the 
community in which it is located, as well as to numerous outlying communities. The 
sample consisted of STEMI patients presenting to the designated hospital, either directly 
or by transfer to the hospital from an outlying area.  
This project focused on a convenience sample of patients, all of whom presented 
to the designated hospital with STEMI between January 1, 2019 and December 31, 2019. 
As the purpose of this DNP project was to evaluate the safety of NTG, only STEMI 
patients (confirmed on 12-lead ECG by a cardiologist) who received NTG were included 
in this project and subsequent data analysis. Additional inclusion criteria were the 
requirements that individuals were 18 years of age or older with chest pain of suspected 





patients must have been eligible to receive NTG upon first medical contact. As alternate 
diagnoses may mimic a STEMI on an ECG (Gu, Svilaas, van der Horst, & Zijlstra, 2008), 
final discharge diagnosis of STEMI was used in conjunction with preliminary STEMI 
identification on ECG analysis.  
The universal definition of STEMI on ECG is new ST-elevation at the J-point ≥ 
0.1 mV in two contiguous leads, other than V2 and V3 (Thygesen et al., 2012). Inferior 
STEMI is identified by ST elevation ≥ 0.1 mV in leads II, III and aVF (Robichaud et al., 
2016; Thygesen et al., 2012). Non-inferior STEMI patients are identified by having ST 
elevation ≥ 0.1 to 0.2 mV in other contiguous leads (Thygesen et al., 2012). For the 
purposes of this project, STEMI location was determined by a member of the 
interventional cardiology group, and was noted in the patient chart along with the culprit 
vessel causing the STEMI noted in the catheterization note. Four cardiologists, all having 
between 10 and 30 years of experience, were active in treating STEMI patients during the 
study timeframe. If patients had infarction in the inferior region as well as another region, 
they were included in the inferior STEMI group. 
Exclusion criteria for this study included anyone who did not receive NTG based 
on initial hemodynamics, pregnant women, anyone with thoracic trauma, and those who 
did not receive NTG based on allergy or recent ingestion of medications for which NTG 
would be contraindicated. Due to variance in protocols among medical providers and 
regional services, patients with initial SBP < 100 mmHg and heart rate < 60 beats per 
minute were still included in this study if they received NTG. Prisoners and individuals 





interpretation while communicating level of chest pain, those individuals who listed their 
primary language as something other than English, were excluded from the study. 
Necessary sample size was calculated using Creative Research Systems (2012) 
sample size calculator, and was based on the population of STEMI patients who received 
NTG. The necessary sample size was determined using a 95% confidence level (⍺=0.05) 
and margin of error of 5%. The necessary sample size based on 76 STEMI patients who 
received NTG was 64 individuals. Due to incomplete data recorded on two patients, data 
were collected on 74 STEMI patients that received NTG in 2019. 
IRB Approval Process 
This project was presented to and approved by the university IRB and hospital 
IRB in May of 2020. During data collection, patient information was de-identified, 
relinquishing the necessity for consent from patients included in the study. Stored data 
were stripped of any patient name, address or birth date to guard anonymity. University 
IRB approval documents may be viewed in Appendix B. To preserve hospital anonymity, 
IRB approval documents are not included from the facility and identifying information 
found on the university IRB was removed. The university IRB acknowledges the receipt 
of the hospital IRB. 
Design and Procedures 
The retrospective chart review and data collection occurred May through June of 
2020, and included STEMI patients presenting to the rural Midwestern hospital from 
January 1, 2019 through December 31, 2019. Patients were identified using the STEMI 
tracking system used by the hospital and STEMI coordinator. Charts were reviewed for 





hemodynamic trends, as well as administration of NTG. Chart review methodology is 
located in Appendix C. Patients that did not meet inclusion criteria were marked as 
ineligible, with no further data collection.  
Measures and Instruments 
Outcome measures were recorded for each patient upon initial contact with 
medical personnel, and included SBP, heart rate, and chest pain intensity. For patients 
that self-administered NTG, initial patient hemodynamics were used from first medical 
contact, with note of self-administration doses. Repeat hemodynamic measurements 
following NTG administration were recorded from the patient chart based on the 
pharmacokinetic onset of NTG. For sublingual and intravenous NTG, post-NTG 
hemodynamics were recorded within a three and fifteen minute period following the 
administration of the medication. Both sublingual and intravenous NTG have an average 
onset between one and three minutes, with average maximum effects occurring between 
five and seven minutes after administration (Food and Drug Administration, 2011; U.S. 
National Library of Medicine, 2020a, 2020b). Patients who received transdermal NTG 
had repeat vital signs recorded between 30 and 60 minutes, due to the delayed onset of 
therapeutic effects and absorption (U.S. National Library of Medicine, 2020c). 
Chest pain intensity was rated by patients on a 0-10 Likert scale, with 0 
representing no chest pain, and 10 representing the maximum rating for chest pain 
intensity. Initial and repeat analysis of chest pain levels were recorded at the same 
interval as repeat hemodynamics to allow for analysis of maximal therapeutic effects on 





sphygmomanometer or automatic external blood pressure monitor, while heart rate was 
obtained from an external cardiac monitoring device or via palpation. 
As in other studies that have evaluated the safety of NTG use in STEMI patients 
(Bosson et al., 2019; Engleberg et al., 2000; Robichaud et al., 2016), hypotension was 
defined as SBP < 90 mmHg and bradycardia as a heart rate < 60 beats per minute. 
Interventions to correct hypotension, including a fluid bolus or vasoactive medication, 
were recorded for each patient if they were required. Chest pain was recorded based on 
the verbal-numeric scale previously mentioned. 
Multiple brands of 12-lead ECG machines were used to collect preliminary ECGs 
on each patient. Due to monitor variation in sensitivity and specificity in the 
identification of STEMI (Garvey, Zegre-Hemsey, Gregg & Studnek, 2016) and low 
positive predictive value of computer interpretation of STEMI (Wilson et al., 2013), 
automated ECG interpretations were not used to determine eligibility. A discharge 
diagnosis of STEMI, which was made by an interventional cardiologist, was essential for 
identifying eligible individuals for this study. Patients’ medical histories were also 
obtained from chart data, which allowed for evaluation of relationships between 
comorbidities and impact on outcome variables. 
Data Analysis 
Data were categorized during extraction from the patients’ charts. The presence of 
STEMI was grouped into either inferior or non-inferior categories. Descriptive statistics 
(mean + standard deviation, percentage) were computed for clinical characteristics of the 





Inferential statistical analyses were computed by statistician J. Rich (personal 
communication, August 16, 2020) using various software programs (Appendix D).  
Fisher’s Exact tests were used to analyze differences in occurrence of 
hypotension, the occurrence of bradycardia, the need for a fluid bolus or vasoactive 
medication, as well as the occurrence of cardiac arrhythmias or cardiac arrest, between 
inferior STEMI patients compared to non-inferior STEMI patients. Multiple linear 
regressions were used to analyze for a difference in the effect of NTG on SBP between 
inferior and non-inferior STEMI patients as well as to compare differences in heart rate 
among STEMI groups, while controlling for comorbidities and interventions. 
To evaluate chest pain, a mixed effects model was used to initially evaluate for 
interactions between time and STEMI location, as well as for morphine administration, 
and their effects on chest pain. This allowed for evaluation of potential differences 
between inferior and non-inferior STEMI groups and to determine if NTG reduced chest 
pain in one group significantly more than in the other. A multivariable linear regression 
was then used to evaluate for a significant reduction in chest pain levels in all STEMI 
patients when comparing pre-NTG administration and post-NTG administration chest 
pain ratings. This model controls for comorbidities, age and other medications that were 
administered to the patients in the study, while analyzing for a significant difference in 
chest pain rating following NTG administration.  
For all regression models, an initial best subsets regression was completed and 
included all of the following variables: age, hypertension, previous MI, gender, diabetes 
mellitus, chronic obstructive pulmonary disease (COPD), cardiac arrhythmias, coronary 





hypotension, vasopressor or fluid bolus, smoking history, morphine, and the use of an 
antihypertensive. Following the best subsets regression, Akaike information criterion 
(AIC) was used as an automated model selection. This allowed for the inclusion of 
variables that had a stronger association to the response variable of interest within each 
separate regression. Following statistical analyses, results and discussion of the research 
questions within this DNP project were compiled, which are presented in the subsequent 
chapter. Additionally, recommendations for future practice and research were identified 





















 The purpose of this DNP project was to explore the safety of NTG use in the 
treatment of patients diagnosed with STEMI by evaluating the effects of NTG on 
hemodynamic measures and angina. The intent of statistical analyses was to compare 
differences in SBP, heart rate, cardiac arrhythmias, and chest pain ratings, between 
inferior and non-inferior STEMI patients that presented at one rural Midwestern hospital 
between January 1, 2019 and December 31, 2019. The research questions for this project 
were: 
1) Does the administration of NTG result in hypotension more often in inferior 
STEMI patients than non-inferior STEMI patients?  
2) Do patients with inferior STEMIs require additional interventions more 
frequently to correct hypotension or bradycardia than non-inferior STEMI patients 
following NTG administration?  
3) Do inferior STEMI patients experience more bradycardia and cardiac 
arrhythmias compared to non-inferior STEMI patients?  
4) Does NTG significantly reduce chest pain levels reported by STEMI patients? 
Similar to previous studies (Bosson et al., 2019; Engleberg et al., 2000; Robichaud et al., 
2016), this project seeks to provide further information on the use of NTG in STEMI 
patients, as well as to provide recommendations for individualized patient care. 
Demographics and Descriptive Statistics 
Seventy-four patients who presented to the Midwestern hospital with the 
diagnosis of STEMI in 2019 received NTG and were eligible for inclusion in this project. 





and transdermal (n=5). Doses of 0.4 mg sublingual varied between one (n= 17), two 
(n=13), three (n=15), or four (n=1) tablets. Patients whom were started initially on 
intravenous NTG also had variable doses, which may be viewed below in Table 1. The 
maximum reported dose of intravenous NTG was 180 micrograms per minute, while the 
lowest infusion dosage was reported as 1 microgram per minute. Titrations of intravenous 
NTG were documented on 18 different patients, with noted increases to reduce SBP and 
chest pain, or decreases to maintain hemodynamic stability. Of the 74 total patients, 
seven individuals self-administered 0.4 mg sublingual NTG prior to initial contact with a 
healthcare provider. Self-administrations doses ranged from one to four tablets taken by 
the patients. One patient who self-administered NTG had initial hypotension but was 
subsequently placed on a NTG infusion.  
Table 1 
 
Initial Route and Dosage of Nitroglycerin 
 






Intravenous   
1 mcg/min 1 
3 mcg/min 1 
5 mcg/min 11 
10 mcg/min 5 
20 mcg/min 1 





Transdermal 2%  
½ inch 3 
1 inch 2 
 
Note. Initial NTG routes were sublingual, intravenous (IV) or transdermal. Twenty two 
patients were initially started on a NTG IV infusion, with doses reported in micrograms 





documented on patients with initial SBP > 150 mmHg. IV NTG infusions were started on 
additional patients (n=23), totaling 45 documented NTG infusions. Transdermal dosage 
of ½ inch equates to 7.5 mg of NTG and 1 inch equates to 15 mg, which is gradually 
absorbed with therapeutic onset between 30 and 60 minutes (U.S. National Library of 
Medicine, 2020c). Transdermal 2% NTG paste of ½ inch equates to approximately 5 
mcg/min of IV NTG, while 1 inch equates to a range of 10 to 39 mcg/min of IV NTG 
(Esposito, Dunham, Granger, Tudor, & Granger, 1998).  
 
Male patients (n= 53) represented a larger proportion of the sample than female 
patients (n=21), representing approximate male and female patient percentages of 72 and 
28, respectively. The average age (± SD) of all individuals included in this project was 
62.8 years (± 11.8 years). Female age was higher with an average of 63.7 (± 12.3) years, 
while males had an average age of 62.5 (± 11.7) years. The most common cardiovascular 
risk factors that were recorded in patients’ health histories included hypertension (n= 41), 
hyperlipidemia (n=34), and any history of smoking (n=32). Additional comorbidities and 
cardiovascular risk factors are provided below in Table 2.   
Table 2  





Coronary Artery Disease 19 
Diabetes Mellitus 17 
Obesity 11 
Previous MI 11 
Chronic Obstructive Pulmonary Disease 6 
 
Note. Diagnoses in patient health histories as listed within the patient chart. Patient 
occurrence represents total number of patients with the specific diagnosis, with 74 total 
patients. Additional diagnostic histories by number of occurrence included cerebral 
vascular accident (n=3), chronic kidney disease (n=4), obstructive sleep apnea (n=3), 
previous coronary artery bypass grafting (n=3), and atrial fibrillation (n=3). Although 
several additional diagnoses were present in the study population, they were not included 





Inferior STEMI was the diagnosis in a larger number of patients (n=44) than non-
inferior STEMI patients (n=30). Of the patients in the inferior STEMI group, the majority 
of patients had the culprit vessel identified as the right coronary artery (RCA) (n=21), 
while non-inferior STEMI patients had the left anterior descending (LAD) coronary 
artery (n=21) identified as the most common culprit vessel. Seven patients in the inferior 
STEMI group had multiple vessels occluded, while three patients in the non-inferior 
STEMI group had multiple vessels occluded. Takotsubo cardiomyopathy was identified 
in one patient within the non-inferior STEMI group (data located in Table 3). 
Table 3 
 
STEMI Location and Culprit Vessels  
 
 Number of Patients 
Vessel Inferior Non-inferior 
RCA 21 - 
LAD 4 21 
DIAG - 3 
OM1/OM2 2 - 
CIRC 7 - 
PDA 1 - 
Multiple 7 3 
Takotsubo - 1 
Unknown 2 2 
Total 44 30 
 
Note. Vessel location as identified in cardiac catheterization laboratory. Unknown is due 
to no catheterization or no specification noted. Coronary arteries by name and 
abbreviation: Right coronary artery (RCA). Left anterior descending (LAD). Diagonal 
(DIAG). Obtuse marginal (OM1/OM2). Circumflex (CIRC). Posterior descending artery 
(PDA). Takotsubo cardiomyopathy is an acute condition that often results in elevated 
cardiac markers and ECG changes (Boyd & Solh, 2020) and can result from a strong 
emotional or physical event that causes left ventricular dilation and acute heart failure. 
With Takotsubo cardiomyopathy, ST- segment elevation can occur, with diagnosis made 







Bradycardia was observed in approximately 31% of patients (n=23) and was the 
most common cardiac aberration. Hypotension occurred in 8% of patients (n=6), while 
cardiac arrhythmias occurred in 12% of patients (n=9). Cardiac arrhythmias included 
ventricular fibrillation (n=3), ventricular tachycardia (n=3) and symptomatic bradycardia 
(n=3). Additional medications that were provided to patients included vasopressors, fluid 




Medications Administered to 2019 STEMI Patients 
 
Medications Number of Patients  
























Note. The above table includes alternate medications that patients received in addition to 
NTG. The number of patients who received a medication does not account for potentially 
receiving medications within the same class or a different class. Patients that received a 
fluid bolus or vasopressor (n=28), analgesia/anxiolytic/sedative (n=38), or an 
antihypertensive(s) (n=19) represents the total number of individual patients that received 







Inferential Statistics to Answer Research Questions 
Research Question 1: Does the administration of NTG result in hypotension more 
often in inferior STEMI patients than non-inferior STEMI patients?  
Inferior STEMI patients had 1.429 times the risk of developing hypotension than 
non-inferior STEMI patients after receiving NTG (OR 1.429, 95% CI [0.248, ∞]). The 
results were not significant (p=0.521), with four inferior STEMI patients and two non-
inferior STEMI patients experiencing hypotension after receiving NTG (comparisons 
illustrated in Figure 1). 
Figure 1 
 




Note. Total number of patients (n=73) compared for hypotension and bradycardia. Total 
number of patients (n=74) for occurrence of administration of corrective medication, as a 
fluid bolus or vasoactive medication to correct hypotension or bradycardia, and 
occurrence of cardiac arrhythmias. There were no significant differences in occurrence of 
hypotension (p=0.521), administration of corrective medications (p=0.530), bradycardia 

























There was a significant difference in SBP noted between inferior STEMI patients 
and non-inferior STEMI patients after receiving NTG (p=0.012), with inferior STEMI 
patients’ mean SBP reduced by 15.23 mmHg more than non-inferior STEMI patients 
after receiving NTG. After receiving NTG, inferior STEMI patients had a mean 
difference in SBP of -19 mmHg (95% CI [-27.4, -10.74]), compared to non-inferior 
STEMI patients, who had a mean difference in SBP of -10.9 mmHg (95% CI [-20.6, -
1.1]). Table 5 below indicates the control variables with significant impacts on mean SBP 
which included antihypertensive medications (p=0.025) and diabetes mellitus (p=0.023), 
with a mean SBP decrease of 15.47 mmHg and mean SBP increase of 16.03 mmHg for 




Effects Estimates of Variables on Systolic Blood Pressure 
 
Variable Estimate Std. Error t p 
Inferior STEMI -15.23 5.90 -2.58 0.012* 
Hypertension 9.98 5.82 1.72 0.091 
Diabetes Mellitus 16.03 6.86 2.34 0.023* 
Obesity 13.14 8.38 1.57 0.122 
Morphine 6.35 5.76 1.10 0.274 
Antihypertensive -15.47 6.74 -2.29 0.025* 
Vasopressor/Bolus 5.34 5.91 0.90 0.370 
(Intercept) -18.59 6.43 -2.89 0.005 
 
Note. P-values are of absolute t-values for each variable. Intercept is included for a point 
of reference, although no inferences will be made based on intercept data. Variables 
included above were decided with AIC, an automated model selection, to allow for 
inclusion of variables that had a stronger association to the response variable (SBP).  








Research Question 2: Do patients with inferior STEMIs require additional 
interventions more frequently to correct hypotension or bradycardia than non-
inferior STEMI patients following NTG administration? 
When analyzing the need for a fluid bolus or corrective medication for 
hypotension or bradycardia, the odds of requiring one of these interventions was 1.086 
times the risk for inferior STEMI patients compared to non-inferior STEMI patients (OR 
1.086, 95% CI [0.439, ∞]). A total of 17 inferior STEMI patients and 11 non-inferior 
STEMI patients received a fluid bolus or corrective medication in this study, equating to 
38.6% of inferior STEMI patients and 36.6% of non-inferior STEMI patients (illustrated 
in to Figure 1). The results were not significant (p=0.530).  
Research Question 3: Do inferior STEMI patients experience more bradycardia and 
cardiac arrhythmias compared to non-inferior STEMI patients? 
The occurrence of bradycardia was not significantly different between inferior 
and non-inferior STEMI groups (p=0.064), with inferior STEMI patients having 2.582 
times the risk of bradycardia than non-inferior STEMI patients (OR 2.582, 95% CI 
[0.940, ∞]). Approximately 40% of inferior STEMI patients (n=17) had at least one 
documented occurrence of bradycardia, while approximately 20% of non-inferior STEMI 
patients (n=6) had at least one documented occurrence of bradycardia. There also was no 
significant difference in heart rate between inferior STEMI and non-inferior STEMI 
groups after NTG (p=0.239), with a lower mean difference in heart rate of 2.84 beats per 
minute observed in inferior STEMI patients following NTG.  
The administration of an antihypertensive and the occurrence of a cardiac 





reduction in mean heart rate of 14 beats per minute associated with antihypertensive 
medications while cardiac arrhythmias were associated with a mean reduction in heart 
rate of approximately nine beats per minute. Other variables evaluated with heart rate 
may be viewed below in Table 6. The risk for developing a cardiac arrhythmia was 1.415 
times higher for inferior STEMI patients (n=6) than non-inferior STEMI patients (n=3) 




Effects Estimates of Variables on Heart Rate 
 
Variable Estimate Std. Error t p 
Inferior STEMI -2.84 2.39 -1.19 0.239 
Diabetes Mellitus -3.59 2.84 -1.26 0.211 
Smoking -4.03 2.37 -1.70 0.094 
Morphine 3.34 2.39 1.40 0.167 
Antihypertensive -14.02 2.76 -5.09 <0.001** 
Cardiac Arrhythmia  -8.65 3.47 -2.50 0.015* 
(Intercept) 6.09 2.44 2.49 0.015 
 
Note. P-values are of absolute t-values for each variable. Intercept is included for a point 
of reference, although no inferences will be made based on intercept data. Significant 
effects were found for antihypertensive medications and cardiac arrhythmias.  
*p < 0.05; **p < 0.001 
 
 
Research Question 4: Does NTG significantly reduce chest pain levels reported by 
STEMI patients? 
Chest pain rating following the administration of NTG did not differ significantly 
between inferior and non-inferior STEMI groups (p=0.391). When rating chest pain on 
the numerical 0 to 10 Likert scale after receiving NTG, inferior STEMI patients reported 
less of a mean chest pain score reduction, with mean chest pain scores 0.61 higher than 





project, NTG administration did significantly reduce the mean chest pain score reported 
by the patients by 1.87 on the 0 to 10 Likert scale (p<0.001). The administration of 
morphine also was associated with significantly increased chest pain levels (p=0.008), 




Effects Estimates of Variables on Chest Pain Rating 
 
Variable Estimate Std. Error t p 
Post-NTG CP -1.87 0.35 -5.31 <0.001** 
Inferior STEMI -0.99 0.76 -1.30 0.200 
Age -0.05 0.03 -1.47 0.148 
CAD 1.24 1.30 -0.96 0.342 
Previous MI -1.46 1.47 -0.99 0.326 
Obesity -1.90 1.17 -1.62 0.114 
Morphine 1.96 0.71 2.77 0.008* 
Analgesics 1.25 1.12 1.11 0.274 
(Intercept) 9.32 2.11 4.42 <0.001 
 
Note. Post-NTG CP represents chest pain (CP) ratings following the administration of 
NTG, with significant reductions for all STEMI patients (p<0.001). Morphine was 
associated with significantly higher CP ratings (p=0.008), while all other variables did 
not have a significant effect on CP changes before and after receiving NTG. Initial 
comparison to evaluate differences in CP reported by inferior and non-inferior STEMI 
patients after receiving NTG was not significant (p=0.391), but due to model selection, 
STEMI location was included and again not significant (p=0.200). 
*p < 0.05; **p < 0.001 
 
Discussion 
The route and dosage of NTG administered to STEMI patients varied greatly 
within this project. Bosson et al. (2019) and Engelberg et al. (2000) reported the use of 
only 0.4 mg sublingual NTG in patients within their studies. Robichaud et al. (2016) also 
reported 0.4 mg sublingual NTG, but included 0.4 mg intranasal NTG spray as a 
treatment modality for patients as well. Although this project did not seek to evaluate the 





pharmacokinetics and therapeutic onset for each route. The variation was attempted to be 
accounted for by documenting medication doses, times, and routes for all medications 
during data extraction to allow for a more complete evaluation.  
The four patients diagnosed with inferior STEMI that experienced hypotension 
had variable initial NTG doses and routes. One patient developed hypotension with a 
documented SBP of 89 mmHg following three doses of 0.4 mg sublingual NTG. Another 
patient developed hypotension and subsequent ventricular fibrillation following two 
doses of 0.4 mg sublingual NTG approximately three minutes following NTG 
administration. Successful management of the patient’s condition occurred, and the 
patient was then placed on five micrograms per minute of intravenous NTG. The third 
patient with inferior STEMI had hypotension following a single dose of 0.4 mg 
sublingual NTG, but was eventually placed on a NTG intravenous infusion at five 
micrograms per minute without further incident. The fourth patient with inferior STEMI 
had “hypotension” documented by an EMS transport crew for a patient who was on a 
titrated dose of NTG, which was at 20 micrograms per minute at the time of 
discontinuation. SBP documented prior to discontinuation was consistently > 90 mmHg, 
with ability to down-titrate the NTG infusion. This patient was restarted on the NTG 
infusion per the cardiologist upon arriving to the cardiac catheterization laboratory.  
The two patients diagnosed with non-inferior STEMI who developed hypotension 
both had received intravenous NTG. One patient had an undocumented amount of NTG, 
but also received diltiazem, metoprolol, and lorazepam before becoming hypotensive. 





developed symptomatic bradycardia and hypotension. The patient responded to 
interventions and remained on the intravenous NTG without further adverse events. 
 The occurrence of hypotension observed in this project following administration 
of NTG does not appear to occur in a predictable fashion, with hypotension occurring 
after variable doses and routes of NTG. Interestingly, three of the six patients who 
developed hypotension remained on intravenous NTG, which supports continued use and 
titration of NTG in an individualized manner in response to each patient. Although it is 
unclear within this project, it is possible that healthcare provider preference or medical 
training played a role in the variability observed between NTG dosages and routes. 
However, regardless of the doses and routes of NTG that were provided to patients in this 
project, there was no significant difference in occurrence of hypotension between patients 
diagnosed with inferior STEMI compared to those with non-inferior STEMI.  
The doses reported in previous studies ranged from a single dose (Engelberg et 
al., 2000), to three doses (Bosson et al., 2019), while Robichaud et al. (2016) accounted 
for unlimited doses. As in this project, Bosson et al. (2019) and Robichaud et al. (2016) 
did not specifically investigate the effects of multiple doses of NTG, but rather for the 
occurrence of hypotension, bradycardia, and adverse events. In this project, the observed 
initiation of intravenous NTG infusions after alternative sublingual or transdermal routes, 
in conjunction with intravenous dose titrations, provides information about how 
management and care of patients diagnosed with STEMI varies within the patient 
encounter. This observation likely relates to adapting to the patients’ needs rather than 





Robichaud et al. (2016) reported several of the same comorbidities and 
cardiovascular risk factors that were controlled for in this project, including previously 
diagnosed CAD, diabetes mellitus, hypertension, and hyperlipidemia. Demographic 
variables were controlled for in statistical analyses within this project to allow for 
identification of potential influences on outcome variables, although the aims of this 
project were not focused on detailed demographic analyses. Demographics were included 
to allow for simple comparisons between patients within this project to demographic 
information of patients with STEMIs in other studies.  
In the analysis of gender frequency, females represented approximately 28% of 
the total patients included in this project. The approximate occurrence of female patients 
with STEMIs reported by Bosson et al. (2019), Engelberg et al. (2000), and Robichaud et 
al. (2016) was 39%, 48%, and 30%, respectively. O’Gara et al. (2013) reported female 
patients representing 30% of all STEMI patients in their study as well. Robichaud et al. 
(2016) and O’Gara et al. (2013) have the most comparable female frequencies reported 
when compared to the frequency of female patients found with this project.  
The average age of all patients in this project (62.8 ± 11.8 years) is similar to that 
noted in a study that evaluated demographics of STEMI patients, with researchers 
reporting an average age of 62 (±13.9) years for all patients (Boyer et al., 2012). The 
study conducted by Bosson et al. (2019), which had similar research questions to those 
analyzed in this project, reported a median age of 63 (IQR 54-75) for patients that 
received NTG. With this information, it does not appear that patients in this project were 
considerably different in demographics, with gender and age occurrences that are 





In evaluating STEMI location, inferior STEMI patients represented approximately 
59% of the patients included in this study, compared to the approximate 47% of patients 
in the study by Robichaud et al. (2016). A higher percentage of patients experienced an 
inferior STEMI in this project than the predicted range of 40% to 50% of patients with 
STEMIs (Warner & Tivakaran, 2020). The RCA was the most commonly occluded 
vessel in the inferior STEMI group, which is most often suspected with inferior STEMI 
identification on a standard 12-lead ECG (Namana et al., 2018). The left circumflex 
artery was the second most commonly occluded coronary artery in this project for 
patients with inferior STEMI, which may indicate left dominant circulation in these 
patients (Namana et al., 2018). For the non-inferior STEMI group, the LAD was the most 
commonly occluded vessel, which is consistent with anterior STEMI and left ventricular 
involvement (Taglieri et al., 2014). The observations of occurrence in this project support 
the most likely culprit vessels associated with each STEMI location (Namana et al., 2018; 
Taglieri et al., 2014), but also that inferior STEMI is not always associated with RCA 
occlusion.  
It is important to note that the inferior STEMI patients in this project represent a 
subgroup of all STEMI patients that presented to the rural Midwestern hospital in 2019. It 
is not clear how this translates to the entire STEMI population that is treated at this 
facility, but does suggest the prevalence of patients that receive NTG with the diagnosis 
of inferior STEMI. Although RV infarct was not evaluated for specifically within this 
project, there were no documented additional diagnostic interventions in patients 





nitrates to patients (Antman et al., 2004; Ibanez, 2018), specific identification of RV 
involvement would be beneficial.  
The patient with Takotsubo cardiomyopathy was included in this study due to 
their clinical presentation, treatment, and diagnosis of STEMI within their medical 
record. Boyd and Solh (2020) discuss how closely ACS and Takotsubo may present, 
including ST segment elevation on a 12-lead ECG tracing. The potential for 
hemodynamic instability in patients with Takotsubo is related to left ventricular 
dysfunction and acute heart failure (Templin et al., 2015) and may be similar to that of 
STEMI patients. The inclusion criteria were met for this patient, even though the patient 
did not have a culprit vessel identified as causing ST-segment elevation due to lack of 
thrombotic or plaque occlusion. Had the patient not had STEMI included in the discharge 
diagnosis made by a cardiologist, the patient would have been excluded from this study.  
Discussion of Research Question 1: Does the administration of NTG result in 
hypotension more often in inferior STEMI patients than non-inferior STEMI 
patients?  
With regard to blood pressure, there is very weak evidence in this project to 
support any significant difference in occurrence of hypotension, defined as SBP < 90 
mmHg, between inferior STEMI patients and non-inferior STEMI patients. The results in 
this project were similar to those reported by Robichaud et al. (2016), with no significant 
difference in occurrence of hypotension between inferior and non-inferior STEMI groups 
(p=0.80). Inferior STEMI patients in this project did, however, have a significantly 
greater reduction in mean SBP compared to non-inferior STEMI patients following 





STEMI groups was significant (p=0.012) after receiving NTG, the lower observed SBP 
in the inferior STEMI group did not equate to a significantly higher occurrence of 
hypotension, as previously reported. This shows that patients with inferior STEMIs 
experienced increased effects from NTG compared to those with non-inferior STEMIs 
within this group of patients, without hemodynamic instability. 
For all patients that received NTG in the study conducted by Bosson et al. (2019) 
there was a median change in SBP of -11 mmHg (IQR -26, 0), while in the study by 
Engleberg et al. (2000), the mean decrease in SBP in patients after receiving NTG was     
-11.8 mmHg (95% CI [-10.7, -13]). In this project, non-inferior STEMI patients had 
similar reduction in mean SBP compared to those in the previously listed studies, with 
mean SBP decrease of -10.9 mmHg, while inferior STEMI patients had a mean SBP 
decrease of -19 mmHg. The previously listed studies did not compare differences in SBP 
between inferior and non-inferior STEMI patients, whereas this project did, showing a 
significant difference in mean SBP reduction between the two groups. The difference in 
mean SBP may suggest increased effects of NTG on patients with inferior STEMIs, 
although Robichaud et al. (2016) found no significant difference in occurrence of drop in 
SBP ≥30 mmHg following NTG between inferior and non-inferior STEMI groups 
(p=0.87). The decrease in SBP ≥ 30 mmHg as investigated in previous studies (Bosson et 
al. 2019; Robichaud et al. 2016) was a threshold used to evaluate the sensitivity of 
patients to nitrates and how those with RV infarct would have a higher incidence in larger 
SBP decreases. Neither study found significant results, indicating the need to reconsider a 
blanket avoidance of nitrates in inferior STEMI patients. Although this project did not 





occurrence of hypotension adds to the evidence supplied by previous studies, as patients 
diagnosed with inferior STEMI in this project did not experience hemodynamic 
instability after receiving NTG.   
Antihypertensive medications were found to be a significant factor in reducing the 
mean SBP while all other variables were controlled for in this project. This suggests that 
the medications were effective in decreasing blood pressure, but also that 
antihypertensive medications may have contributed to the observed difference in 
decreased mean SBP between each inferior and non-inferior STEMI groups. This 
observation warrants further investigation, as the effects of antihypertensive medications 
were not compared with statistical analyses between patients with inferior and non-
inferior STEMIs in this project. Although morphine and hemodynamic supportive 
measures did not have significant effects on SBP in this project, the regression model 
identified these variables as affecting the outcome variable of SBP more than other 
demographic variables or comorbidities.  
Although it is not clear why NTG was associated with a significantly increased 
mean SBP in patients with diabetes, there are some potential explanations. Muntner, 
Whelton, Woodward, and Carey (2018) note that 66.3% of patients with diabetes have 
concurrent hypertension by American Diabetes Association (ADA) guidelines, while 
77.1 % of patients with diabetes have hypertension by the ACC and AHA guidelines. The 
high prevalence in general, regardless of which guideline is used for defining 
hypertension, illustrates the close relationship between diabetes and hypertension. This 
may represent an overall higher SBP in patients presenting with STEMI with concurrent 





patients with diabetes may not respond to NTG with arterial dilation as well due to 
impaired nitric oxide pathways, which can occur with damaged endothelium (Tessari et 
al., 2010; Vavuranakis et al., 1999). As nitroglycerin converts to nitric oxide within the 
body (Kim, Kerndt, & Schaller, 2020), reduced efficacy may result given impaired 
metabolic pathways in diabetes. Although this is not a definite explanation for the 
observed significant increase in this project, it may indicate a need to investigate other 
factors relating to STEMI patients with diabetes mellitus and how standard medications 
may impact that specific population.  
Discussion of Research Question 2: Do patients with inferior STEMIs require 
additional interventions more frequently to correct hypotension or bradycardia 
than non-inferior STEMI patients following NTG administration? 
In comparing inferior and non-inferior STEMI groups and the number of patients 
requiring a medication to correct hypotension or bradycardia, there is a lack of evidence 
to support any true difference in need between the groups based on the occurrences 
observed in this project. Individuals who received these pharmacological interventions 
may not have needed the specific intervention based on hemodynamic data reviewed 
within the charts. Multiple individuals in both inferior and non-inferior STEMI groups 
received fluid boluses without concomitant hypotension, with no clear basis for 
administration identified during the chart review. The fluid boluses may have been 
administered as a prophylactic measure or fluid challenge to the patients, but were not 
documented as such. A total of 28 patients received a fluid bolus or vasoactive 
medication, while only six patients experienced true hypotension and three experienced 





to fluid or medication administration and remained stable within the timeframe of interest 
for this project. Fluid bolus and vasoactive medication were included in the multivariable 
linear regression in the analysis of SBP following administration of NTG, however, these 
variables were not associated with a significant increase in SBP (refer to Table 5). Six 
patients experienced a ventricular arrhythmia, but none died within the timeframe of 
interest in this project. 
Discussion of Research Question 3: Do inferior STEMI patients experience more 
bradycardia and cardiac arrhythmias compared to non-inferior STEMI patients?  
Inferior STEMI patients in this project had lower mean heart rates than non-
inferior STEMI patients, which ultimately was not a significant finding. In the entire 
observed population, there were 23 patients who had bradycardia, with a higher 
occurrence in inferior STEMI patients. Three patients in this project had symptomatic 
bradycardia, all of whom had inferior STEMIs, but all of whom also responded to 
medical interventions. Many patients with bradycardia were either noted to have stable 
bradycardia upon initial contact or have one documented heart rate below 60. This is 
similar to the observations made in Bosson et al. (2019), with 75% of bradycardic 
patients having a heart rate between 50 and 59 beats per minute, with a comparable 
occurrence of bradycardia noted in patients with RCA and non-RCA occlusions.  
 Antihypertensive medications were observed to have a significant effect on heart 
rate in this project. Of these medications, metoprolol was administered to 100% (n=19) of 
patients who received an antihypertensive medication. Diltiazem (n=1) and hydralazine 
(n=1) were also administered to separate patients in addition to at least one dose of 





blocker, has the ability to cause a decrease in heart rate, cardiac output, and blood 
pressure (Morris & Dunham, 2020). Similarly, Roolvink et al. (2016) identified a 
significant heart rate reduction in STEMI patients who received metoprolol. As the 
predominant antihypertensive medication provided to patients in this project, metoprolol 
and its effects on outcome variables of heart rate and SBP had strong hemodynamic 
influences identified in patients within this project.  
 When controlling for other variables, cardiac arrhythmias also affected mean 
heart rate in patients, with a mean reduction of approximately eight beats per minute. 
This observation points to the potential for adverse events following NTG administration, 
with lower heart rates observed in patients who experienced a cardiac arrhythmia. 
However, there is no evidence in this project that the occurrence of a cardiac arrhythmia 
differed significantly between inferior and non-inferior patients. STEMI location in this 
project was not a strong predictor of an adverse event occurring, while other variables 
with strong effects on SBP and heart rate may have been more likely to contribute to the 
occurrence.  
Discussion of Research Question 4: Does NTG significantly reduce chest pain levels 
reported by STEMI patients? 
There was no significant difference in chest pain reduction between inferior and 
non-inferior STEMI patients, meaning no single group experienced a greater benefit from 
NTG in this project. Interestingly, morphine was associated with increased mean chest 
pain, which might be attributed to higher initial and subsequent chest pain scores reported 
by individuals who received this medication. This may be because morphine was truly 





recommended by Frampton et al. (2020), since the use of morphine inhibits the 
therapeutic effects of commonly used antiplatelet medications.  
Kendrick and Strout (2005) identified a change in pain rated on the numeric pain 
scale of 1.39 ± 1.05 (95% CI, 1.27-1.51) to be significant, which is how chest pain was 
evaluated in this project. As the verbal analog scale (VAS) for pain can be correlated with 
the numeric pain scale (Holdgate, Asha, Craig, & Thompson, 2003), pain reduction 
around 1.3 was also considered significant in an alternative study using VAS to assess 
pain (Todd, Funk, Funk, & Bonacci, 1996). The mean reduction in chest pain scores in 
this project was 1.9 for all STEMI patients, representing a significant reduction in pain 
and demonstrating the benefit of NTG and its ability to reduce chest pain in STEMI 
patients in this project. Mean chest pain reduction reported by both Bosson et al. (2019) 
and Engleberg et al. (2000), was 2.6, again providing support for the role of NTG in chest 
pain reduction, including chest pain experienced by STEMI patients. The results from 
this project, as well as the results in previous studies, indicate that patients experiencing 
STEMI benefit from the effects of NTG by significant reductions in chest pain.  
Clinical Implications for Practice 
This DNP project contributes to clinical practice by identifying variables that 
influence hemodynamic variables as well as differences that occur in inferior and non-
inferior STEMI patients who received NTG. NTG, which was provided to a large number 
of patients with the diagnosis of inferior STEMI, did not result in a significant difference 
in occurrence of hypotension when compared to non-inferior STEMI patients. Although 
there should not be generalizations transferred directly to practice, there are implications 





The concern relating to NTG administration to patients with inferior STEMI 
identified on a 12-lead ECG is RV infarct and the potential for hemodynamic collapse. In 
this project, RV infarct was not evaluated for specifically. Even though patients with 
inferior STEMI received NTG with few adverse events, it is unclear if these patients did 
have RV involvement that precipitated adverse events. Further investigation in the effects 
of NTG on patients with inferior STEMI and concomitant RV infarct would be 
beneficial, as well as diagnostic tools to identify RV involvement. 
One intervention that could assist healthcare providers in identifying RV infarct 
would be to perform a right-sided ECG. Increasing views of the heart by adding 
additional leads to a standard 12-lead ECG can increase sensitivity to diagnosing STEMI, 
improve infarct location identification, and identify infarctions that may not be visible on 
a standard 12-lead ECG (Tragardh, Claesson, Wagner, Zhou, & Pahlm, 2007; Vogiatzis 
et al., 2019). Bischof et al. (2018) recommend evaluation of lead V4R to identify RV 
involvement during an acute MI, because of low sensitivity and specificity of standard 
12-lead ECG analysis. Similarly, Kanovsky et al. (2016) discuss the value of the right-
sided ECG in identifying RV infarct, as patients with occlusions to the RCA, circumflex 
artery and LAD may have RV involvement that may not be recognized using standard 
12-lead ECG analysis. No patients in this study had a right-sided ECG analysis, which 
would be one recommendation for future patients presenting to the rural Midwestern 
hospital. The right precordial leads would assist healthcare providers in identifying RV 
involvement, which would help to guide individualized treatment.  
This project identified that NTG was associated with a significant reduction in 





providers should be providing analgesia to patients, and doing so with evidence to 
support such interventions. As newer research shows that opioids reduce the efficacy of 
antiplatelet medications used in STEMI patients (Frampton et al., 2020), it is important to 
use medications that provide the most overall benefit. As adverse events were not 
significantly different between inferior and non-inferior STEMI patients in this project, 
the safety of NTG by these standards supports the viability of this medication as a 
possible analgesic choice for both inferior and non-inferior STEMI patients. 
As patients with RV infarct have higher immediate mortality rates (Noguchi et al., 
2019), implementing a right-sided ECG would help to more easily identify RV infarct, 
guiding treatment of the patient. Providers would have additional information from which 
to base decisions, including making informed decisions on whether or not to withhold 
NTG from patients. Additionally, with the identification of RV infarct, providers would 
be able to anticipate the need for fluid resuscitation, vasoactive medications and potential 
external pacing (Inohara, Kohsaka, Fukuda, & Menon, 2013; Noguchi et al., 2019), and 
respond to the patients’ needs in the event of hemodynamic collapse. 
Recommendations for Future Research 
Several recommendations for future research can be made based on results in this 
DNP project. The first recommendation would be for a prospective study to evaluate the 
effects of NTG on hemodynamic variables and chest pain on inferior and non-inferior 
STEMI patients. This project, as a retrospective review, has limitations in generalizability 
to STEMI patients and cannot explain direct causality, for which a prospective study 





In a prospective study or similar future retrospective studies, more strict criteria 
may be warranted when evaluating the occurrence of bradycardia, with modifications to 
what identifies a patient as bradycardic. Recommendations may be to include patients 
that experience symptomatic bradycardia or consistently documented bradycardia with 
heart rates < 60 beats per minute. This way, a transient or asymptomatic decrease in heart 
rate would not be considered as an adverse event in patients. In this project, one 
occurrence of a documented heart rate below 60 beats per minute was counted toward an 
occurrence of bradycardia, even though only 3 patients had hemodynamic instability and 
several others had one heart rate below 60 beats per minute, providing an occurrence rate 
but not necessarily a clear picture of patient condition.  
As NTG doses and routes of administration varied among patients within this 
project, a future prospective study or similar retrospective study would control for this 
variable. Although it is possible to evaluate patient hemodynamics based on therapeutic 
onset and pharmacokinetic properties of NTG, a controlled dose and route would help 
remove potential limitations with the results. With the removal of variation, the effects of 
NTG on hemodynamic variables may be more clearly identified in STEMI patients. 
The effects of metoprolol on STEMI patients should also be evaluated, as this 
medication served as a variable that had significant effects on both SBP and heart rate 
within this project. Research has been conducted to evaluate potential benefits of 
metoprolol prior to PCI and its impact on infarct size (García-Ruiz et al., 2016; Roolvink 
et al., 2016), however, the data does not have consistent results with regard to the 





patients. As 19 patients in this study received this medication, further investigation on its 
effects on this patient population would be beneficial. 
Another recommendation for future research would be to include the 
identification of RV infarct within the study sample. This could be done in comparative 
analyses between STEMI patients with and without RV infarct, but also as a simple 
observation of occurrence. Because RV infarction occurs at a variable frequency within 
inferior STEMI patient populations (Bischof et al., 2018; Nagam et al., 2017), further 
analysis into the specific topic would be a beneficial contribution to the knowledge 
regarding STEMI patients. Although this project did not seek to identify patients with RV 
infarct within the sample, the results of the effects of NTG on inferior STEMI patients 
contribute to the research suggesting the elimination of avoidance of NTG in individuals 
with inferior STEMI identification. Additional diagnostic tools, such as the right-sided 
ECG, may be utilized to identify RV involvement with the goal of removing hesitancy in 
the provision of NTG to patients with inferior STEMI identified on ECG analysis. 
Strengths 
To mitigate potential errors that may occur with retrospective chart reviews, this 
DNP project aimed to follow recommendations on how to conduct such a project (Kaji, 
Schriger, & Green, 2014; Vassar & Holzmann, 2013). The sample size exceeded the 
minimum number of individuals that was determined by the sample size calculator, 
reducing probability of type II error. Although several patients were excluded from the 
multiple variable regressions evaluating blood pressure and heart rate due to incomplete 
data for these specific analyses models, there were 66 and 67 patients, which exceeded 





approval was obtained from both the hospital and through Northern Michigan University 
prior to data collection, and a data template was used to organize extracted data to allow 
for organization and to maintain patient confidentiality. These measures as recommended 
by Vassar and Holzmann (2013), increase the strength of studies by adhering to 
systematic data extraction and upholding patient confidentiality. Additionally, exclusion 
criteria for this project addressed vulnerable populations, which addresses ethical 
considerations that may arise when conducting a retrospective chart review (Vassar & 
Holzmann, 2013).  
Limitations 
One of the main limitations identified in this project is the retrospective design 
and subsequent sampling technique. Because the sampling of patients was a convenience 
sample, bias is not accounted for due to the non-random sampling techniques used. 
Because of this, generalizations cannot be made about entire STEMI populations (Vassar 
& Holzmann, 2013), as analyses describe only the observations within the specific 
sample of patients within this project. Although effects estimates were provided for 
variables within this project, their influence on outcome measures should be viewed as 
associations and only applied to patients within this project due to lack of randomization. 
Additionally, selection bias is introduced to the project with the exclusion of patients 
from statistical analyses due to missing data (Kaji et al., 2014). Although the minimum 
number of required individuals as determined by the sample size calculator was surpassed 
with each analysis, it is important to address potential selection bias resulting from the 
exclusion of patients. Other limitations in this project include conducting the project at a 





frame. Including data on patients from additional locations and extending the time frame 
from which patients could be included may have been beneficial in reducing bias as well 
as when drawing observational inferences. Additionally, the doses and routes of NTG 
administration were not controlled for within this project, and may be considered a 
limitation due to the high variability among patients.  
Conclusion 
  As NTG remains a frontline medication used in STEMI patients, both to reduce 
angina and as an antihypertensive (de Alencar Neto, 2018), this DNP project sought to 
contribute further to what is known about the effects and safety of NTG in STEMI 
patients. The purpose of this DNP project was to explore the safety of NTG use in the 
treatment of patients diagnosed with STEMI by evaluating the effects of NTG on 
hemodynamic measures and angina. Outcome variables of SBP, heart rate, occurrence of 
cardiac arrhythmias, and need for medical interventions to correct hemodynamic 
instability thus were compared between inferior and non-inferior STEMI patients who 
received NTG. As the AHA discourages the use of NTG in patients with RV infarct 
(Antman et al., 2004), further investigation into the provision of NTG to patients with 
inferior STEMI and RV infarct is warranted. Although identification of the occurrence of 
RV infarct was not conducted within this project, diagnostic measures to improve 
identification of RV infarct could provide valuable information to healthcare providers, 
and subsequently used to guide individualized patient care. 
 In this project, there was no significant difference in occurrence of hypotension in 
inferior STEMI patients and non-inferior STEMI patients who received NTG. Mean SBP 





significant increased need for medical intervention. There was also no significant 
difference in occurrence of cardiac arrhythmias or bradycardia between the two groups, 
but inferior STEMI patients did have lower mean heart rates. Additionally, NTG 
provided patients with significant reductions in chest pain in both inferior and non-
inferior STEMI groups, supporting its therapeutic use in this patient population. Overall, 
these results suggest the general safety of NTG in patients eligible to receive it, even 
without specific diagnostic measures to identify RV involvement.  
For advanced practice nurses, the information in this project may be a valuable 
component to their role in providing individualized patient care. As a member of the 
interdisciplinary team, it is necessary to consider individualized treatment options for 
patients. This includes medications, associated safety concerns prior to administration, 
and potential adverse events that may occur in patient populations. Advanced practice 
nurses may use clinical judgement and incorporate additional diagnostic tools in the 
treatment of STEMI patients, including the use of right-sided ECG analysis in inferior 
STEMI patients. This may help guide the provision of medications such as NTG, which 
may relieve angina associated with STEMI, and ultimately improve the level of 
individualized patient care. 
In this project, NTG use in inferior STEMI patients did not result in significantly 
more adverse events than in non-inferior STEMI patients, even without the identification 
of RV infarct. This suggests reevaluating the avoidance of NTG based on concerns of 
hemodynamic adverse events due to potential RV infarct. Inferior STEMI patients should 
receive a right-sided ECG to detect RV infarct, with lead V4R serving as the most 





sensitivity in detecting the presence of RV infarct with a right-sided ECG can help guide 
healthcare providers in providing highly-individualized care. As in similar studies 
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Chart Review Methodology 
 
1. Obtain Institutional Review Board (IRB) approval 
2. Construct template for data extraction  
3. Obtain list of patient’s with STEMI 
a. Contingent on STEMI tracking system 
b. May include individuals that activated a STEMI alert – requiring further 
inquiry   
4. Access patient information 
a. Begin with searching for discharge diagnosis of STEMI 
b. Not all patients that activate a STEMI response are true STEMIs 
c. If patient has discharge diagnosis of STEMI, continue with chart review 
for that patient 
d. If discharge diagnosis does not include STEMI, patient excluded from 
project 
5. Review chart for patient inclusion and exclusion criteria 
a. Inclusion criteria 
i. Received NTG 
ii. Chest pain of suspected cardiac origin 
iii. 18 years of age or older 
iv. Diagnosis of STEMI (ECG/expert cardiologist diagnosis) 
b. Exclusion criteria 
i. Did not receive NTG 
ii. Pregnant women 
iii. Thoracic trauma 
iv. Vulnerable populations 
v. English as secondary language 
6. Begin extraction of data into template 
a. Patient demographics: Age, gender, past medical history relating to 
cardiac risk factor (ie: Previous MI, Diabetes mellitus, smoking) 
b. Identify through documentation on patient location and region of STEMI 
i. Culprit vessel causing STEMI (coronary artery) 
ii. Inferior/Anterior/Posterior/Lateral 
iii. Obtained from cardiology documentation 
c. Extract all heart rates, blood pressures, oxygen saturations, respirations 
with associated time (oxygen saturation and respirations not evaluated in 
this project) 
d. Extract patient rated chest pain and times 
e. Extract all medications with associated administration time, route, and 
dose 





7. Sort data 
a. Hemodynamics prior to administration of NTG and first documented after 
NTG based on medication onset and half-life to be used for ratio level 
analyses on effects of NTG 
b. Review all hemodynamics for each patient 
i. Note if patient was hypotensive or bradycardic based on 
parameters 
ii. Note if patient experienced a cardiac arrhythmia or adverse event 
iii. Note corrective medications, either as vasopressor or fluid bolus 
and if patient was responsive medically to interventions 
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